Yttrium-90

Last updated
Yttrium-90, 90Y
General
Symbol 90Y
Names yttrium-90, 90Y, Y-90
Protons (Z)39
Neutrons (N)51
Nuclide data
Half-life (t1/2)64.60±0.43 h [1]
Isotopes of yttrium
Complete table of nuclides

Yttrium-90 (90
Y
) is a radioactive isotope of yttrium. [2] Yttrium-90 has found a wide range of uses in radiation therapy to treat some forms of cancer. [3] Along with other isotopes of yttrium, it is sometimes called radioyttrium.

Contents

Decay

90
Y
 undergoes beta particles emissions/decay (β− decay) to zirconium-90 with a half-life of 64.1 hours [3] and a decay energy of 2.28 MeV with an average beta energy of 0.9336 MeV. [4] It also produces 0.01% 1.7 MeV [5] photons during its decay process to the 0+ state of 90Zr, followed by pair production. [6] The interaction between emitted electrons and matter can lead to the emission of Bremsstrahlung radiation.

Production

Yttrium-90 is produced by the nuclear decay of strontium-90 which has a half-life of nearly 29 years and is a fission product of uranium used in nuclear reactors. As the strontium-90 decays, chemical high-purity separation is used to isolate the yttrium-90 before precipitation. [7] [8] Yttrium-90 is also directly produced by neutron activation of natural yttrium targets (Yttrium is mononuclidic in 89Y) in a nuclear research reactor.

Medical application

90Y plays a significant role in the treatment of hepatocellular carcinoma (HCC), leukemia, and lymphoma, although it has the potential to treat a range of tumors. [9] Trans-arterial radioembolization is a procedure performed by interventional radiologists, in which 90Ymicrospheres are injected into the arteries supplying the tumor. [10] The microspheres come in two forms: resin, in which 90Y is bound to the surface, and glass, in which 90Y is directly incorporated into the microsphere during production. [11] Once injected, the microspheres become lodged in blood vessels surrounding the tumor and the resulting radiation damages the nearby tissue. [12] The distribution of the microspheres is dependent on several factors, including catheter tip positioning, distance to branching vessels, rate of injection, properties of particles, like size and density, and variability in tumor perfusion. [12] Radioembolization with 90Y significantly prolongs time-to-progression (TTP) of HCC, [13] has a tolerable adverse event profile, and improves patient quality of life more than do similar therapies. [14] 90Y has also found uses in tumor diagnosis by imaging the Bremsstrahlung radiation released by the microspheres. [15] Positron emission tomography after radioembolization is also possible. [16]

Post-treatment imaging

Following treatment with 90Y, imaging is performed to evaluate 90Y delivery and absorption to evaluate coverage of target regions and involvement of normal tissue. This is typically performed using Bremsstrahlung imaging with single-photon emission computed tomography CT (SPECT/CT), or using 90Y position imaging with positron emission tomography CT (PET/CT).

Bremsstrahlung imaging after 90Y therapy

As 90Y undergoes beta decay, broad spectrum bremsstrahlung radiation is emitted and is detectable with standard gamma cameras or SPECT. [17] [18] These modalities provide information about radioactive uptake of 90Y, however, there is poor spatial information. [17] [18] Consequently, it is challenging to delineate anatomy and thereby evaluate tumor and normal tissue uptake. This led to the development of SPECT/CT, which combines the functional information of SPECT with the spatial information of CT to allow for more accurate 90Y localization. [17] [18]

Positron imaging after 90Y therapy

PET/CT and PET/MRI have superior spatial resolution compared to SPECT/CT because PET detects positron pairs produced from the decay of emitted positrons, negating the requirement for a physical collimator. [17] [18] This allows for better assessment of microsphere distribution and dose absorption. However, both PET/CT and PET/MRI are less widely available and more costly. [17] [18]

See also

Related Research Articles

<span class="mw-page-title-main">Positron emission tomography</span> Medical imaging technique

Positron emission tomography (PET) is a functional imaging technique that uses radioactive substances known as radiotracers to visualize and measure changes in metabolic processes, and in other physiological activities including blood flow, regional chemical composition, and absorption. Different tracers are used for various imaging purposes, depending on the target process within the body.

<span class="mw-page-title-main">Medical imaging</span> Technique and process of creating visual representations of the interior of a body

Medical imaging is the technique and process of imaging the interior of a body for clinical analysis and medical intervention, as well as visual representation of the function of some organs or tissues (physiology). Medical imaging seeks to reveal internal structures hidden by the skin and bones, as well as to diagnose and treat disease. Medical imaging also establishes a database of normal anatomy and physiology to make it possible to identify abnormalities. Although imaging of removed organs and tissues can be performed for medical reasons, such procedures are usually considered part of pathology instead of medical imaging.

<span class="mw-page-title-main">Hepatocellular carcinoma</span> Medical condition

Hepatocellular carcinoma (HCC) is the most common type of primary liver cancer in adults and is currently the most common cause of death in people with cirrhosis. HCC is the third leading cause of cancer-related deaths worldwide.

<span class="mw-page-title-main">Nuclear medicine</span> Medical specialty

Nuclear medicine, is a medical specialty involving the application of radioactive substances in the diagnosis and treatment of disease. Nuclear imaging is, in a sense, radiology done inside out, because it records radiation emitted from within the body rather than radiation that is transmitted through the body from external sources like X-ray generators. In addition, nuclear medicine scans differ from radiology, as the emphasis is not on imaging anatomy, but on the function. For such reason, it is called a physiological imaging modality. Single photon emission computed tomography (SPECT) and positron emission tomography (PET) scans are the two most common imaging modalities in nuclear medicine.

A radioligand is a microscopic particle which consists of a therapeutic radioactive isotope and the cell-targeting compound - the ligand. The ligand is the target binding site, it may be on the surface of the targeted cancer cell for therapeutic purposes. Radioisotopes can occur naturally or be synthesized and produced in a cyclotron/nuclear reactor. The different types of radioisotopes include Y-90, H-3, C-11, Lu-177, Ac-225, Ra-223, In-111, I-131, I-125, etc. Thus, radioligands must be produced in special nuclear reactors for the radioisotope to remain stable. Radioligands can be used to analyze/characterize receptors, to perform binding assays, to help in diagnostic imaging, and to provide targeted cancer therapy. Radiation is a novel method of treating cancer and is effective in short distances along with being unique/personalizable and causing minimal harm to normal surrounding cells. Furthermore, radioligand binding can provide information about receptor-ligand interactions in vitro and in vivo. Choosing the right radioligand for the desired application is important. The radioligand must be radiochemically pure, stable, and demonstrate a high degree of selectivity, and high affinity for their target.

Transcatheter arterial chemoembolization (TACE) is a minimally invasive procedure performed in interventional radiology to restrict a tumor's blood supply. Small embolic particles coated with chemotherapeutic drugs are injected selectively through a catheter into an artery directly supplying the tumor. These particles both block the blood supply and induce cytotoxicity, attacking the tumor in several ways.

<span class="mw-page-title-main">Neuroimaging</span> Set of techniques to measure and visualize aspects of the nervous system

Neuroimaging is the use of quantitative (computational) techniques to study the structure and function of the central nervous system, developed as an objective way of scientifically studying the healthy human brain in a non-invasive manner. Increasingly it is also being used for quantitative research studies of brain disease and psychiatric illness. Neuroimaging is highly multidisciplinary involving neuroscience, computer science, psychology and statistics, and is not a medical specialty. Neuroimaging is sometimes confused with neuroradiology.

A gallium scan is a type of nuclear medicine test that uses either a gallium-67 (67Ga) or gallium-68 (68Ga) radiopharmaceutical to obtain images of a specific type of tissue, or disease state of tissue. Gallium salts like gallium citrate and gallium nitrate may be used. The form of salt is not important, since it is the freely dissolved gallium ion Ga3+ which is active. Both 67Ga and 68Ga salts have similar uptake mechanisms. Gallium can also be used in other forms, for example 68Ga-PSMA is used for cancer imaging. The gamma emission of gallium-67 is imaged by a gamma camera, while the positron emission of gallium-68 is imaged by positron emission tomography (PET).

Copper-64 (64Cu) is a positron and beta emitting isotope of copper, with applications for molecular radiotherapy and positron emission tomography. Its unusually long half-life (12.7-hours) for a positron-emitting isotope makes it increasingly useful when attached to various ligands, for PET and PET-CT scanning.

TheraSphere is a radiotherapy treatment for hepatocellular carcinoma (HCC) that consists of millions of microscopic, radioactive glass microspheres being infused into the arteries that feed liver tumors. These microspheres then embolize, lodging themselves in the liver's capillaries and bathing the malignancy in high levels of yttrium-90 radiation. It is currently approved as a Humanitarian Device, meaning effectiveness has not been proven, for patients as a neoadjuvant to surgery or transplantation by the U.S. Food and Drug Administration and is being used at a number of clinical centers in the United States.

<span class="mw-page-title-main">Selective internal radiation therapy</span>

Selective internal radiation therapy (SIRT), also known as transarterial radioembolization (TARE), radioembolization or intra-arterial microbrachytherapy is a form of radionuclide therapy used in interventional radiology to treat cancer. It is generally for selected patients with surgically unresectable cancers, especially hepatocellular carcinoma or metastasis to the liver. The treatment involves injecting tiny microspheres of radioactive material into the arteries that supply the tumor, where the spheres lodge in the small vessels of the tumor. Because this treatment combines radiotherapy with embolization, it is also called radioembolization. The chemotherapeutic analogue is called chemoembolization, of which transcatheter arterial chemoembolization (TACE) is the usual form.

Nuclear medicine physicians, also called nuclear radiologists or simply nucleologists, are medical specialists that use tracers, usually radiopharmaceuticals, for diagnosis and therapy. Nuclear medicine procedures are the major clinical applications of molecular imaging and molecular therapy. In the United States, nuclear medicine physicians are certified by the American Board of Nuclear Medicine and the American Osteopathic Board of Nuclear Medicine.

SIR-Spheres microspheres are used to treat patients with unresectable liver cancer. These are mostly patients with hepatocellular carcinoma (HCC), metastatic colorectal cancer (mCRC), or metastatic neuroendocrine tumours (mNET).

Preclinical imaging is the visualization of living animals for research purposes, such as drug development. Imaging modalities have long been crucial to the researcher in observing changes, either at the organ, tissue, cell, or molecular level, in animals responding to physiological or environmental changes. Imaging modalities that are non-invasive and in vivo have become especially important to study animal models longitudinally. Broadly speaking, these imaging systems can be categorized into primarily morphological/anatomical and primarily molecular imaging techniques. Techniques such as high-frequency micro-ultrasound, magnetic resonance imaging (MRI) and computed tomography (CT) are usually used for anatomical imaging, while optical imaging, positron emission tomography (PET), and single photon emission computed tomography (SPECT) are usually used for molecular visualizations.

<span class="mw-page-title-main">DOTA-TATE</span> Eight amino-acid long peptide covalently bonded to a DOTA chelator

DOTA-TATE is an eight amino acid long peptide, with a covalently bonded DOTA bifunctional chelator.

<span class="mw-page-title-main">Brain positron emission tomography</span> Form of positron emission tomography

Brain positron emission tomography is a form of positron emission tomography (PET) that is used to measure brain metabolism and the distribution of exogenous radiolabeled chemical agents throughout the brain. PET measures emissions from radioactively labeled metabolically active chemicals that have been injected into the bloodstream. The emission data from brain PET are computer-processed to produce multi-dimensional images of the distribution of the chemicals throughout the brain.

Interventional oncology is a subspecialty field of interventional radiology that deals with the diagnosis and treatment of cancer and cancer-related problems using targeted minimally invasive procedures performed under image guidance. Interventional oncology has developed to a separate pillar of modern oncology and it employs X-ray, ultrasound, computed tomography (CT) or magnetic resonance imaging (MRI) to help guide miniaturized instruments to allow targeted and precise treatment of solid tumours located in various organs of the human body, including but not limited to the liver, kidneys, lungs, and bones. Interventional oncology treatments are routinely carried out by interventional radiologists in appropriate settings and facilities.

Sandip Basu is an Indian physician of Nuclear Medicine and the Head, Nuclear Medicine Academic Program at the Radiation Medicine Centre. He is also the Dean-Academic (Health-Sciences), BARC at Homi Bhabha National Institute and is known for his services and research in Nuclear Medicine, particularly on Positron emission tomography diagnostics and Targeted Radionuclide Therapy in Cancer. The Council of Scientific and Industrial Research, the apex agency of the Government of India for scientific research, awarded him the Shanti Swarup Bhatnagar Prize for Science and Technology, one of the highest Indian science awards for his contributions to Nuclear Medicine in 2012.

Radiation lobectomy is a form of radiation therapy used in interventional radiology to treat liver cancer. It is performed in patients that would be surgical candidates for resection, but cannot undergo surgery due to insufficient remaining liver tissue. It consists of injecting small radioactive beads loaded with yttrium-90 into the hepatic artery feeding the hepatic lobe in which the tumor is located. This is done with the intent of inducing growth in the contralateral hepatic lobe, not dissimilarly from portal vein embolization (PVE).

<span class="mw-page-title-main">Peptide receptor radionuclide therapy</span> Type of radiotherapy

Peptide receptor radionuclide therapy (PRRT) is a type of radionuclide therapy, using a radiopharmaceutical that targets peptide receptors to deliver localised treatment, typically for neuroendocrine tumours (NETs).

References

  1. ↑ Chetham-Strode A, Kinderman EM (February 1, 1954). "The Half-Life of Yttrium-90". Physical Review. 93 (5): 1029. Bibcode:1954PhRv...93.1029C. doi:10.1103/physrev.93.1029. ISSN   0031-899X.
  2. ↑ DeVita VT, Lawrence TS, Rosenberg SA, Weinberg RA, DePinho RA (1 April 2008). DeVita, Hellman, and Rosenberg's cancer: principles & practice of oncology. Lippincott Williams & Wilkins. p. 2507. ISBN   978-0-7817-7207-5 . Retrieved 9 June 2011.
  3. 1 2 "Y-90 Handling Precautions" (PDF). Berkeley Lab. Archived from the original (PDF) on 15 January 2018. Retrieved 2015-07-15.
  4. ↑ "Live Chart of Nuclides". International Atomic Energy Agency. 2009. Retrieved 2020-06-02.
  5. ↑ Rault E, Vandenberghe S, Staelens S, Lemahieu T (2009). Optimization of Yttrium-90 Bremsstrahlung Imaging with Monte Carlo Simulations. 4th European Conference of the International Federation for Medical and Biological Engineering. Vol. 22. Berlin, Heidelberg: Springer. pp. 500–504. ISBN   9783540892083 . Retrieved 21 October 2013.
  6. ↑ d'Arienzo, Marco (2013). "Emission of β+ Particles Via Internal Pair Production in the 0+ – 0+ Transition of 90Zr: Historical Background and Current Applications in Nuclear Medicine Imaging". Atoms. 1 (1): 2–12. Bibcode:2013Atoms...1....2D. CiteSeerX   10.1.1.361.5234 . doi: 10.3390/atoms1010002 . S2CID   17248197.
  7. ↑ Chinol M, Hnatowich DJ (September 1987). "Generator-produced yttrium-90 for radioimmunotherapy". Journal of Nuclear Medicine. 28 (9): 1465–70. CiteSeerX   10.1.1.543.5481 . PMID   3625298.
  8. ↑ "PNNL: Isotope Sciences Program - Yttrium-90 Production". PNNL. February 2012. Retrieved 2012-10-23.
  9. ↑ Tong AK, Kao YH, Too CW, Chin KF, Ng DC, Chow PK (June 2016). "Yttrium-90 hepatic radioembolization: clinical review and current techniques in interventional radiology and personalized dosimetry". The British Journal of Radiology. 89 (1062): 20150943. doi:10.1259/bjr.20150943. PMC   5258157 . PMID   26943239.
  10. ↑ Kallini JR, Gabr A, Salem R, Lewandowski RJ (May 2016). "Transarterial Radioembolization with Yttrium-90 for the Treatment of Hepatocellular Carcinoma". Advances in Therapy. 33 (5): 699–714. doi:10.1007/s12325-016-0324-7. PMC   4882351 . PMID   27039186.
  11. ↑ Semaan, Sahar; Makkar, Jasnit; Lewis, Sara; Chatterji, Manjil; Kim, Edward; Taouli, Bachir (November 2017). "Imaging of Hepatocellular Carcinoma Response After 90Y Radioembolization". American Journal of Roentgenology. 209 (5): W263–W276. doi:10.2214/AJR.17.17993. ISSN   0361-803X. PMID   29072955.
  12. 1 2 "Understanding SIR-Spheres Y-90 Resin Microspheres". Colorectal Cancer Alliance. 23 October 2015. Retrieved 2019-10-21.
  13. ↑ Salem R, Gordon AC, Mouli S, Hickey R, Kallini J, Gabr A, et al. (December 2016). "Y90 Radioembolization Significantly Prolongs Time to Progression Compared With Chemoembolization in Patients With Hepatocellular Carcinoma". Gastroenterology. 151 (6): 1155–1163.e2. doi:10.1053/j.gastro.2016.08.029. PMC   5124387 . PMID   27575820.
  14. ↑ Salem R, Gilbertsen M, Butt Z, Memon K, Vouche M, Hickey R, et al. (October 2013). "Increased quality of life among hepatocellular carcinoma patients treated with radioembolization, compared with chemoembolization". Clinical Gastroenterology and Hepatology. 11 (10): 1358–1365.e1. doi: 10.1016/j.cgh.2013.04.028 . PMID   23644386.
  15. ↑ Wright CL, Zhang J, Tweedle MF, Knopp MV, Hall NC (2015-04-22). "Theranostic Imaging of Yttrium-90". BioMed Research International. 2015: 481279. doi: 10.1155/2015/481279 . PMC   4464848 . PMID   26106608.
  16. ↑ Kao, Y. H.; Steinberg, J. D.; Tay, Y. S.; Lim, G. K.; Yan, J.; Townsend, D. W.; Takano, A.; Burgmans, M. C.; Irani, F. G.; Teo, T. K.; Yeow, T. N.; Gogna, A.; Lo, R. H.; Tay, K. H.; Tan, B. S.; Chow, P. K.; Satchithanantham, S.; Tan, A. E.; Ng, D. C.; Goh, A. S. (2013). "Post-radioembolization yttrium-90 PET/CT - part 1: Diagnostic reporting". EJNMMI Research. 3 (1): 56. doi: 10.1186/2191-219X-3-56 . PMC   3726297 . PMID   23883566.
  17. 1 2 3 4 5 Rice, Mitchell; Krosin, Matthew; Haste, Paul (October 2021). "Post Yttrium-90 Imaging". Seminars in Interventional Radiology. 38 (4): 460–465. doi:10.1055/s-0041-1735569. ISSN   0739-9529. PMC   8497086 . PMID   34629714.
  18. 1 2 3 4 5 Tong, Aaron K. T.; Kao, Yung Hsiang; Too, Chow Wei; Chin, Kenneth F. W.; Ng, David C. E.; Chow, Pierce K. H. (June 2016). "Yttrium-90 hepatic radioembolization: clinical review and current techniques in interventional radiology and personalized dosimetry". The British Journal of Radiology. 89 (1062): 20150943. doi:10.1259/bjr.20150943. ISSN   1748-880X. PMC   5258157 . PMID   26943239.
This page is based on this Wikipedia article
Text is available under the CC BY-SA 4.0 license; additional terms may apply.
Images, videos and audio are available under their respective licenses.